| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
Human Endogenous Metabolite
Pentacosanoic acid targets lipid metabolism and membrane biology. As a very long-chain fatty acid, it is involved in the structure and function of biological membranes. The degree of demyelination in adrenoleukodystrophy is related to the pentacosanoic to docosanoic acid ratios. |
|---|---|
| ln Vitro |
In vitro, pentacosanoic acid is used as a valuable tool in elucidating the role of lipids in biological membranes and their implications in health and disease. It is a long-chain saturated fatty acid used in lipidomics and biophysical studies. The compound is used to study membrane structure, lipid metabolism, and fatty acid signaling.
|
| ln Vivo |
Adrenoleukodystrophy's degree of demyelination is correlated with the behenic acid to behenic acid ratios (C25:0/C22:0 and C26:0/C22:0). The parts that are most affected, where the active process is finished, are mostly home to the intermediate fraction's saturated fatty acids (C24:0, C25:0, and C26:0). The identification of a region with a high concentration of long-chain fatty acids was the cause of the absence of histopathological alterations [1]. The frontal lobe margins are often where areas of myelin loss but axonal retention are most noticeable. lesions. Pentacosanoic acid (C25:0) and hexacanoic acid (C26:0) represent the midpoint of a bell-shaped distribution of very long-chain fatty acids esterified to cholesterol [1].
In vivo, pentacosanoic acid is an endogenous metabolite and a very long-chain fatty acid. The degree of demyelination in adrenoleukodystrophy is related to the pentacosanoic to docosanoic acid ratios (C25:0/C22:0). The compound is involved in lipid metabolism and may play a role in neurological disorders. |
| Enzyme Assay |
In vitro enzyme assays for fatty acid metabolism involve incubating pentacosanoic acid with enzymes such as acyl-CoA synthetase or elongases in buffer at pH 7.4. The compound is used as a substrate for studying very long-chain fatty acid metabolism. Fatty acid levels are quantified by GC-MS or LC-MS/MS. The compound's effects on membrane properties are studied using lipid bilayer models.
|
| Cell Assay |
For in vitro cell assays, cells are cultured in medium supplemented with pentacosanoic acid at concentrations of 0.1-10 mM, often complexed with BSA. Cell viability is assessed by MTT assay. Fatty acid uptake and metabolism are analyzed by LC-MS/MS. The compound's effects on lipid metabolism and membrane function are assessed by measuring lipid intermediates and membrane fluidity.
|
| Animal Protocol |
For in vivo animal studies, pentacosanoic acid is administered to rodents via oral gavage at doses of 10-100 mg/kg. Blood and tissue samples are collected for pharmacokinetic analysis. Fatty acid levels are quantified by GC-MS or LC-MS/MS. In adrenoleukodystrophy models, the ratio of pentacosanoic acid to docosanoic acid (C25:0/C22:0) is measured as a marker of demyelination.
|
| ADME/Pharmacokinetics |
Pentacosanoic acid (MW 382.66) has a molecular formula of C25H50O2. It is a 25-carbon long-chain saturated fatty acid and a very long-chain fatty acid. The compound is stable under standard storage conditions. It is the conjugate acid of a pentacosanoate. It is an endogenous metabolite.
|
| Toxicity/Toxicokinetics |
The compound is for research use only. No specific toxicity data are available. As an endogenous fatty acid, it is expected to have low toxicity at physiological concentrations. High doses may affect lipid metabolism. Standard safety precautions should be followed.
|
| References | |
| Additional Infomation |
Pentacosanoic acid is a straight-chain saturated fatty acid, and also a very long-chain fatty acid. It is the conjugate acid of pentacosanate. It has been reported that Pentacosanoic acid exists in Senecio scandens, Hippophae rhamnoides, and other organisms with relevant data.
Pentacosanoic acid (CAS# 506-38-7) is an endogenous metabolite and research reagent used primarily in lipidomics, biophysical studies, and research on adrenoleukodystrophy. It has not been investigated in clinical trials nor approved as a therapeutic drug. The compound is used to study the role of lipids in biological membranes and their implications in health and disease. It is a very long-chain fatty acid. |
| Molecular Formula |
C25H50O2
|
|---|---|
| Molecular Weight |
382.66
|
| Exact Mass |
382.381
|
| CAS # |
506-38-7
|
| PubChem CID |
10468
|
| Appearance |
White to off-white solid powder
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
412.4±8.0 °C at 760 mmHg
|
| Melting Point |
83 °C
|
| Flash Point |
185.0±13.3 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.460
|
| LogP |
11.94
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
23
|
| Heavy Atom Count |
27
|
| Complexity |
288
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCCCCCCCCCCCCCCCC(=O)O
|
| InChi Key |
MWMPEAHGUXCSMY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H50O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25(26)27/h2-24H2,1H3,(H,26,27)
|
| Chemical Name |
pentacosanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 5 mg/mL (13.07 mM)
Ethanol: < 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.5 mg/mL (1.31 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.5 mg/mL (1.31 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6133 mL | 13.0664 mL | 26.1329 mL | |
| 5 mM | 0.5227 mL | 2.6133 mL | 5.2266 mL | |
| 10 mM | 0.2613 mL | 1.3066 mL | 2.6133 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
